Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AdCh3NSmut + MVA-NSmut
- Development stage
- Phase 2
- Lead developer
- ReiThera
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
AdCh3NSmut + MVA-NSmut is a **prime-boost vaccine regimen** for hepatitis C virus (HCV), utilizing two non-replicating recombinant viral vectors. AdCh3NSmut is a modified replication-incompetent chimpanzee adenovirus vector encoding a genetically inactivated NS region (NSmut) of HCV genotype 1b, covering key non-structural proteins (NS3, NS4a, NS4b, NS5a, NS5b). MVA-NSmut uses Modified Vaccinia Ankara (MVA), also encoding the NSmut antigen. The regimen primes the immune system with AdCh3NSmut and boosts the response with MVA-NSmut, inducing strong, broad, and sustained HCV-specific T-cell responses. Both vectors are genetically engineered not to replicate or integrate, with the NS5B polymerase inactivated for safety. Developed for the prevention or treatment of HCV infection, this combination is under clinical investigation and has shown strong immunogenicity and favorable safety in early-phase trials[1][2][3].
- Other names
- AdCh3NSmut1/MVA-NSmutChAd3-NSmut + MVA-NSmut
02
Targets
NS3 (Dengue virus NS3 protein)NS4A (Hepatitis C virus NS4A)NS4B (Hepatitis C virus NS4B)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on AdCh3NSmut + MVA-NSmut.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AdCh3NSmut + MVA-NSmut.